The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.

Summit Therapeutics (SMMT) stock faced a downgrade at H.C. Wainwright after late-stage trial data for Merck’s (MRK) lung cancer drug sac-TMT. Read more here.

By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking ...

Samsung Bioepis Co Ltd, a biopharmaceutical company committed to realizing healthcare that is accessible to everyone, has announced that the phase 1 study on SB27, a proposed biosimilar to Keytruda ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of ...

Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, ...

The phase 3 trial was evaluating two doses of anti-LAG-3 antibody fianlimab in combination with PD-1 inhibitor Libtayo ...